Technology Profiles
 Profile Detail
Use of lauryl gallate for prevention and treatment of infections caused by the African Swine Fever Virus (ASFV) (09 ES 28G2 3CG5)
Investigations carried out in Spanish Research Institutes, on cell cultures infected by the African swine fever virus (ASFV), showed that non-cytotoxic concentrations of LG dramatically reduced the production of several ASFV isolates, preventing the dissemination of ASF disease. They want to reach a license agreement whit companies interested in.
Country: Spain
Type: OFFER
Date: 05.03.2010
This new therapeutical use of LG is based on the results obtained on Vero cell cultures, that allow the productive ASFV infection, proving that i) the viability of Vero cells and swine macrophages was maintained in the presence of LG concentrations up to 30-60 µM, and ii) the presence of LG in the range of 1-10 µM effectively reduced the production of different field or laboratory isolates of ASFV in Vero cells or swine macrophages, preventing the productive infection of these cells and the dissemination, therefore, of the disease caused by the virus.
These results can be extrapolated with therapeutical or prophylactic purposes to the animal groups at risk. In view of the low-profile toxicity of LG, its use as antiviral agent must be suitable, considering, moreover, that the complex clinical assays required for new antiviral compounds should be overcome in the case of LG.
Innovative Aspects:
The most important innovations of this technology are:
1.- There is no current technology, since no effective vaccine or treatment against ASF have been described to reduce viral pathogenicity.
2.- It should be possible to generate a "defence ring" to protect porcine farms from the contamination by nearby ASFV outbreaks, in particular in poor countries where control or compensating national programmes are not promoted.
3.- The absence of LG-induced toxicity has been repeatedly proved by its use as antioxidant and preservative in food industry.
4.- LG is a non-conventional antiviral compound, probably directed against some cellular target(s), opening the possibility to inhibit different ASFV isolates (field or laboratory, virulent or not, current or emerging), with no restriction to a particular virus strain/structure.
5.- An additional possibility is the control/prevention of other virus diseases by the broad antiviral activity of LG (effective against virus like Herpes, Influenza, Vaccinia, Porcine transmissible gastroenterirtis,&)
The principal advantages are:
- Possibility to avoid the systematic sacrifice of porcine population in or nearby ASFV outbreaks, particularly in poor countries.
- Crossed protection against other virus-induced diseases of human and veterinary interest.
Degree of development:
Patents/Rights: Patent(s) applied for but not yet granted
Requested Cooperation: License Agreement, Joint further development
- Type of partner sought: Pharmaceutical company.
- Specific area of activity of the partner: Animal health.
- Task to be performed: Licence agreement.
Type of Organisation:
Status: NEW
| 
